key: cord-0964344-h6a4f4lz authors: Rampogu, Shailima; Gajula, Rajesh Goud; Lee, Gihwan; Kim, Myeong Ok; Lee, Keun Woo title: Unravelling the Therapeutic Potential of Marine Drugs as SARS-CoV-2 Inhibitors: An Insight from Essential Dynamics and Free Energy Landscape date: 2021-05-29 journal: Comput Biol Med DOI: 10.1016/j.compbiomed.2021.104525 sha: cc3ea85cfc6622bcf78a2d81e3dfdc1a7b0c51af doc_id: 964344 cord_uid: h6a4f4lz Coronavirus disease 2019 (COVID-19) is an ongoing pandemic. The virus that causes the disease, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), predominantly infects the respiratory tract, which may lead to pneumonia and death in severe cases. Many marine compounds have been found to have immense medicinal value and have gained approval from the Food and Drug Administration (FDA), and some are being tested in clinical trials. In the current investigation, we redirected a number of marine compounds toward SARS-CoV-2 by targeting the main protease (M(pro), PDB ID: 6Y2F), subjecting them to several advanced computational techniques using co-crystallised ligand as the reference compound. The results of the binding affinity studies showed that two compounds, eribulin mesylate (eri) and soblidotin (sob), displayed higher docking scores than did the reference compound. When these compounds were assessed using molecular dynamics simulation, it was evident that they demonstrated stable binding at the binding pocket of the target protein. The systems demonstrated stable root mean square deviation and radius of gyration values, while occupying the binding pocket during the simulation run. Furthermore, the essential dynamics and free energy landscape exploration revealed that the protein had navigated through a minimal energy basin and demonstrated favourable conformation while binding to the proposed inhibitors. Collectively, our findings suggest that two marine compounds, namely eri and sob, show potential as SARS-CoV-2 main protease inhibitors. Coronavirus disease 2019 is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) (Gorbalenya et al., 2020) . Infection, which is often manifested as fever and dry cough, may lead to pneumonia (N. Wang et al., 2020) . Coronaviruses (CoVs) belong to the Coronaviridae family and possess a large single-stranded RNA genome (Zheng, 2020) . Of the four identified classes of Coronaviridae, SARS-CoV-2 is classified into the beta class, which includes Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) (Pal et al., 2020) . Upon analysing the genome of COVID-19, two large polyproteins were detected, ORF1 and ORF2, along with four structural and six accessory proteins. The polyprotein is cleaved to generate 16 nonstructural proteins (nsps) (Khailany et al., 2020; Snijder et al., 2003; Yoshimoto, 2020) . The structural proteins are the envelope protein (E), membrane protein (M), nucleocapsid (N), and spike protein (S). The spike protein of the virus facilitates the entry of the virus into the host (human) when attached to the receptor protein, angiotensin-converting enzyme 2(ACE2). This is followed by the generation of nsps that promote the replication of the virus (Astuti and Ysrafil, 2020; Although a host of drugs has been used against the disease and some of them have reached clinical trials , the search for an effective drug is still under investigation. In a number of recent studies, drug repurposing approaches have been applied, employing both computational and experimental methods (Arun et al., 2020; Chen, Xu, et al., 2020; Dotolo et al., 2020; Kandeel and Al-Nazawi, 2020; Li et al., 2020; Mohapatra et al., 2020; Rampogu and Lee, 2021a; Singh et al., 2020; Sultana et al., 2020) . However, the need for effective drugs remains. Targeting the proteins involved in viral replication is a superior approach to hindering viral growth and, consequently, its spread (Bojkova et al., 2020) . In this study, we aimed to find effective drug candidates against SARS-CoV-2 main protease (M pro ), given the evidence that inhibiting M pro leads to the obstruction of viral replication . The viral target M pro has garnered wide attention because of its crucial role in processing the polyproteins as a result of translation from viral RNA . This enzyme performs its functions at no less than 11 cleavage sites located on the larger polyprotein 1ab. The principal recognising site is Leu-Gln↓(Ser, Ala, and Gly). Interestingly, human proteases with similar cleavage specificity have not been reported, suggesting that the identified inhibitors are nontoxic . Structurally, M pro is made up of three domains: domain I comprises the residues from 8-101; domain II consists of the residues from 102-184, displaying an antiparallel β-barrel structure; and domain III corresponds to residues 201-303, enclosing five α-helices organised into a large antiparallel globular cluster (Jin et al., 2020) . Domain III is connected to domain II by a long loop region (residues 185-200) and has a catalytic dyad with Cys-His residues. The substrate-binding site is stationed in a groove located between domains I and II (Jin et al., 2020) . This site has been explored for the design and discovery of new potential drugs. Nature offers a variety of sources for drug discovery and development, including plants, animals, microorganisms, and marine organisms (Guo, 2017) . Marine-derived scaffolds are instrumental in adding more compounds to the process of drug discovery and development (Guo, 2017; Lee et al., 2015) . By 1974, two marine-derived natural products (cytarabine, Ara-C and vidarabine, Ara-A) had been included in pharmacopoeia to treat human disease (Mayer et al., 2010 ) and a few have gained approval from the U.S. Food and Drug Administration (FDA), while some are in clinical trials (Malve, 2016) . Marine compounds obtained from various sources have been used to treat certain viral diseases (Yasuhara-Bell and Lu, 2010) . Prior to this, reports exist regarding the use of marine drugs against SARS (De Lira et al., 2007; Park et al., 2013) . Interest in marine compounds has increased recently, and the search for novel marine scaffolds for SARS-CoV-2 is now underway. Accordingly, some researchers have focused on the use of computational methods to retrieve potential hits against SARS-CoV-2 (Gentile et al., 2020; Khan et al., 2020; Muteeb et al., 2020; Vijayaraj et al., 2020) Encouraged by these reports, we have repurposed the marine-derived compounds which are FDA approved and are at different phases of clinical trials against M pro , in order to discover putative inhibitors to mitigate the disease. The target chosen for the current investigation was the main protease (M pro ) bearing the PDB ID: 6Y2F , complexed with the inhibitor O6K . The protein was downloaded in PDB format and upgraded using Discovery Studio v.18 (DS). Subsequently, the presence of gaps and missing residues was assessed using the Clean Protein tool accessible on DS and minimised using the Minimise and Refine Protein protocol. Prior to refinement, the heteroatoms and water molecules were dislodged (Rampogu et al., 2020b) . The small molecules chosen for the current study were compounds obtained from the marine sources chosen from the literature (Malve, 2016) . Specifically, the research work included the collection of compounds which are approved by the FDA and/or are in the investigative stage, as detailed in Table 1 . The small molecules were downloaded from the PubChem database in 2D format and were escalated to the DS to obtain their 3D structures. The ligands were prepared using the Prepare Ligands protocol available in DS, which assists in the preparation of ligands by performing tasks such as removing duplicates, enumerating isomers and tautomers, and generating 3D conformations. The prepared ligands were minimised using a Full Minimisation module available with the DS. Binding affinity studies were performed using the CDOCKER module obtained from DS (Wu et al., 2003; Puratchikody et al., 2016) . CDOCKER employs the CHARMm-based molecular Correspondingly, random conformations of the ligand were generated using high-temperature MD. These conformations were further translated into binding sites. Subsequently, candidate poses were generated using random rigid-body rotations followed by simulated annealing. A final minimisation was then applied to refine the ligand poses. This programme allows the refinement docking of any number of ligands with a single protein receptor. The active site was chosen around the inbound ligand for all atoms and residues within a radius of 11 Å. The best pose was chosen based on the highest docking score from the largest cluster, displaying interactions with the key residues. For superior evaluation of the putative inhibitors, the co-crystallised ligand was considered as a reference compound. The binding free energies were then determined for each ligand and receptor. The free energy of binding for a receptor-ligand complex can be calculated from the free energies of the complex, receptor, and ligand. Here, the binding energies were calculated using the Calculate Binding Energies protocol available in DS. To elucidate the nature of small molecules at the binding pocket of the protein, MDS was performed with GROMACS v2016.16 (Van Der Spoel et al., 2005) . The main objective of using MDS is to estimate the stability of the protein-ligand complex and to delineate the interaction at the atomistic level, as reported earlier (Rampogu et al., 2018; Rampogu and Lee, 2021b) . The ligand topologies were obtained from SwissParam (Zoete et al., 2011) using the CHARMM27 all-atom force field. A dodecahedron water box consisting of a TIP3P water model was used to solvate the system, and, subsequently, counter ions were added. The system was then minimised, followed by coupling of the protein and ligand. The coupling process was performed by a double equilibration method using the conserved number of particles (N), system volume (V), temperature (T) (NVT), and a constant number of particles (N), system pressure (P), and temperature (T) (NPT) for 1 ns each. The NPT ensembles were escalated to the MDS for 100 ns. The pressure of the system was monitored using a Parrinello-Rahman barostat (Parrinello, 1981) . The protein backbone was restrained, while the solvent molecules and counter ions were permitted to move. The geometry of the molecules was maintained by the LINCS algorithm, which constrained the bond length (Hess et al., 1997) . All analyses were carried out using visual molecular dynamics (VMD) (Humphrey et al., 1996) and DS. The results were evaluated according to the root mean square deviation (RMSD), root mean square fluctuations (RMSF), radius of gyration (Rg) (Rampogu et al., 2020a) , potential energy, number of hydrogen bonds, distance between the hydrogen bond interacting residues and ligand atoms, interaction energy, and the mode of ligand binding. Additionally, the essential dynamics and free energy landscape investigations were carried out to gain a deeper understanding of the dynamics between the proteins and ligands (Mishra et al., 2020) . Molecular docking between the protein and the ligands was performed to determine the binding affinities between them and predict the predictive binding modes (Rampogu et al., 2020b) . The selected ligands were allowed to generate 50 conformations and were subsequently clustered. From the largest cluster, the poses with higher -CDOCKER interaction energy were chosen as the best poses and lower binding energies, as tabulated in To elucidate the behaviour of small molecules at the binding pocket of the target, an MDS study was conducted. MDS serves as an alternative to experimental analysis and can simulate the system at the atomistic scale (Wu et al., 2019) . The obtained results were assessed according to the RMSD, radius of gyration (Rg), potential energy, RMSF, mode of ligand binding, number of hydrogen bond analysis, distance measure, and interaction energy. The protein stability corresponding to its conformation can be judged by the variations generated, if any, while the simulation period rationally inferred that smaller deviations greater the stability of the protein (Aier et al., 2016) . The RMSD profiles were plotted for the backbone atoms of the protein to determine if there were any significant deviations in the graphs. The three systems have projected the RMSD plots below 0.3 nm, with an average of 0.17, 0.17, and 0.18 nm, respectively, for the reference compound (ref), eri, and sob. Additionally, we measured the RMSD of the complexes to explore the stability dynamics of the protein with its respective ligand complexes. The obtained results show that the proteinref, protein-eri, and protein-sob complexes displayed an RMSD of 0.23, 0.23, and 0.24 nm, respectively. Although the complexes showed a slight increase in the RMSD profiles, they were still within the acceptable range. These findings indicate that the systems are stable, as shown in Figure 1a . Protein structure compactness is measured as the radius of gyration (Rg), inferring that the three-state folding of proteins is more compact than that of proteins in two-state folding (Lobanov et al., 2008) . In the present study, the compactness of the protein backbone was studied during the entire simulation run. It was noted that the protein was highly stable, with an Rg value ranging from 2.16 to 2.28 nm, as shown in Figure 1b . While ref and eri demonstrated firm Rg values, sob showed a peak at 93,920 ps, which decreased to a plateau at 94,910 ps, and a steady equilibrium was noted thereafter, as shown in Figure 1b and Supplementary Figure 1 . Overall, the three systems were firmly greater compact. Another parameter, the potential energy, was also calculated. The three systems established a steady potential energy, between -834,000 and -827,000 kJ/mol, as shown in Figure 1c . The RMSF is defined as a measure of residue-specific flexibility (Dong et al., 2018) . Here, RMSF was conducted on the protein backbone of the three systems. No fluctuations were observed in the backbone residues, as shown in Figure 1d . It is noteworthy that Asp48 appeared to have shown marginal fluctuations from the loop region. Interestingly, this residue was not a major part of the binding pocket. Barring Asp48, the remaining residues were highly stable (without any fluctuations), maintaining the integrity of the target protein. against the X-ray crystal structure. The results showed that the compounds were accommodated at the binding pocket as that of the innate compound O6K, as shown in Figure 2 , surrounded by key residues. J o u r n a l P r e -p r o o f Page 13 of 37 The hydrogen bond interactions were monitored throughout the simulations. The obtained results indicate that the hydrogen bonds were persistent throughout the simulation run for all three systems. Furthermore, the hydrogen bonds ranged between 1 and 9, with an average of 2.5, 1.9, and 2.1, respectively, for ref, eri, and sob, as shown in Figure 3a . These results suggest that the ligand interacts with the target protein during the entire simulation and lies within the binding pocket. The intermolecular interactions showed that the ref compound formed four hydrogen bonds with the residues His41, Ser144, Cys145, and Glu166, respectively, as shown in Figure 4a and Table 1 , rendered by an acceptable bond length. This compound formed interactions via alkyl and π-alkyl interactions with the residues His164 and Pro168. Notably, the residue Met49 formed a π-sulfur linkage and Met165 formed carbon hydrogen bonds. Furthermore, the residues Thr25, Thr26, Leu27, Gly143, Leu167, Val186, Asp187, and Gln189 held the ligand via van der Waals interactions and firmly nestled the ligand at the binding pocket, as shown in Figure 4d . Compound eri formed hydrogen bond interactions with Met165 and Glu166, respectively, established by an acceptable bond length, as shown in Figure 4b and Table 1 . The residue Pro168 formed a π-alkyl interaction with the ligand, helping to stabilise the position of the compound at the binding pocket. The residues Thr26, Arg188, Gly189, and Ala191 formed carbon hydrogen bonds. Additionally, the residues Thr25, Leu27, His41, Asn142, Gly143, Cys145, His164, Leu167, Thr190, and Glu192 assisted in the appropriate positioning of the ligand at the active site, as shown in Figure 4e . The compound sob generated hydrogen bond interactions with Cys44 and Asn142 with a permissible limit, as depicted in Figure 4c and Table 1 . The key residue, Met165, prompted an alkyl interaction with the ligand. The residues Ser46 and Glu166 generated residues such as Thr25, Thr26, Leu27, His41, Val42, Thr45, Glu47, Asp48, Met49, Cys145, Leu167, Pro168, His164, Arg188, Asp187, and Gln189 held the ligand via van der Waals interactions, positioning the ligand at the binding pocket of the target, as shown in Figure 4f . To gain additional insights into the binding of the putative inhibitors at the binding pocket of the protein, the distance between the hydrogen bond interacting atoms and the ligand atoms was measured. This analysis revealed that the initial distance was greater, varying between 0.2 and 0.8 nm, and a steady state was reached during the progression of the simulation run, as shown in Figure 5 and 6. The eri structure generated hydrogen bond interactions with adjacent residues Met165 and Glu166, respectively. The distance between Met165 and its corresponding ligand atom was approximately 0.6 nm until 15,000 ps and dropped thereafter. Remarkably, from 20,000 ps, the bond distance was maintained at approximately 0.3 nm, with an average of 0.26 nm, as shown in Figure 5a . Glu166 formed a relatively stable interaction with its ligand atom from 20,000 ns, with an average of 0.26 nm. Notably, the distance in the initial simulation run appeared to be longer and projected a length of 0.4 nm, which then declined and reached a steady profile from 20,000 ps, as shown in Figure 5b . Likewise, the distance analysis of the interacting residues forming the hydrogen bond between the target protein and sob was reviewed. The modelling of residue Cys44 projected a firm interaction with an average of 0.20 nm. The initial distance was observed at 0.5 nm, which gradually dropped at approximately 6,500 ps, with no fluctuations thereafter. The distance plot revealed an increase at approximately 87,120 ps, while it was within the acceptable limit of 0.3 nm, as shown in Figure 6c . The residue Asn142 formed two hydrogen bond interactions with the same ligand atom O6. Asn142:HD21 demonstrated an average distance of 0.2 nm, with an increase between 45,000 ps to 60,000 ps, as shown in Figure 6a . Similarly, the distance between Asn142:HD22 showed a steady profile with a marginal increase from 55,000 to 60,000 ps and projected an average of 0.25 nm, as shown in Figure 6b . From these distance profiles, it can be stated that the key residues interact with the ligands by an acceptable length, indicating their strong interaction, as shown in Figure 5 and 6. Furthermore, to assess the strength of the interaction between the protein and the small molecule, the interaction energies were computed and read according to the term LJ-SR: protein-lig. All the systems displayed an interaction energy between -250 and -100 kJ/mol. The average value of the interaction energy for ref, eri, and sob was computed as -170, -203, and -179 kJ/mol, respectively, as illustrated in Figure 3b . These findings suggest that the identified natural compounds have higher binding affinity toward the target than the cocrystallised compound, highlighting their usability as an alternative therapy for COVID-19. The function of a protein is governed by transformations between different conformations. A protein in its functional form The structure of a protein will show varying degrees of flexibility/rigidity, especially with respect to the residues at the binding pocket (Mishra et al., 2020) . To understand the comprehensive motion of the protein utilised in the conformational space during the 100-ns simulation run, an ED analysis was performed using the two projection PCs, PC1 and PC2. PC1 and PC2 were computed by diagonalising the co-variance matrix of eigenvectors to specifically label the subspaces in which a major part of the protein dynamics occurs. The ED plots clearly indicated that the protein was localised in a minor conformational space. Nevertheless, the sob structure seems to have occupied relatively more conformational space along PC2, inferring that the protein might have moved across a wide range of conformational space before obtaining the equilibrated state (Mishra et al., 2020) , as shown in Figure 7 . To gain further insight into the conformational transition behind the protein-ligand interaction, free energy landscape (FEL) descriptions are useful. FEL facilitates accurate details of the minimum energy conformations of biomolecular ensembles and are generated using the Boltzmann inversion (F=-RT InP), where P is defined as the 2D probability distribution, pertaining to the first two PCs, PC1 and PC2, when taken as reaction coordinates (Mishra et al., 2020) . Our findings demonstrate that the compounds, eri and sob, bind with the protein via a minimum free energy pathway, as shown in Figure 8 . from lower (red) to higher (blue) energy. Repurposing FDA drugs is an important strategy to discover effective drugs against SARS-CoV-2. Specifically, hindering the proteins involved in viral replication would be a valuable technique. Correspondingly, in the current work, we targeted the protein that is essential in the proteolytic process, the M pro of SARS-CoV-2. Earlier, we have worked on M pro and nsp16 (2'-O -methyltransferase) to discover potential inhibitors against SARS-CoV-2 (Rampogu et al., 2021; Lee, 2021c, 2021d) . Natural compounds offer a host of therapeutic applications, and many have been repurposed against COVID-19. Nevertheless, the potential of natural compounds extracted from marine habitats has not been well studied. Remarkably, even FDA approved marine drugs/derivatives and those in clinical trials offer to be a good alternative. Therefore, in the current study we utilised both approved marine drugs/derivatives and drugs in clinical trials to identify putative inhibitors that inhibit M pro . Our thorough computational analysis yielded two compounds, sob and eri, as promising inhibitors against M pro . It has been recently reported that eri is a potential inhibitor of M pro (Kalhotra et al., 2021) . Sob (auristatin PE or TZT-1027) is a synthetic product obtained from dolastatin 10, which acts as a vascular disrupting compound involved in the disintegration of vasculature within the tumour and demonstrates tubulin inhibitory potential (Malve, 2016) (Mayer et al., 2010) . Eri (E7389 or halichondrin B) is a natural polyether macrolide obtained from marine sponges. Preclinical animal model studies have demonstrated that eri has potent anticancer activity. It acts by irreversible antimitotic action, thereby causing cell death via the apoptotic pathway (Malve, 2016; Mayer et al., 2010) . The binding pocket of SARS-CoV-2 M pro comprises four subsites consisting of key residues (Gimeno et al., 2020; Kanhed et al., 2020; Świderek and Moliner, 2020) . Our identified inhibitors prompted crucial interactions with these residues through several interactions. Both compounds were accommodated in the binding site throughout the simulations, as shown in Figure 9 . The compound eri was held by the hydrogen bond interactions and alkyl and π alkyl interactions by the residues arising from the lower part of the active site, as shown in Figure 10a , and is encircled by the residues via van der Waals interactions, facilitating strong positioning of the compound. Likewise, compound sob showed two hydrogen bond interactions with the residues from the top and bottom portions of the binding pocket, as shown in Figure 10b . The residues from various other subsites prompted van der Waals interactions to firmly secure the compound at the binding pocket, as shown in Figure 10b . The compound eri generated interactions with the key residues Met165 and Glu166 rendered by hydrogen bonds, while the compound sob formed van der Waals interactions with Glu166 and alkyl interactions with Met165, respectively. Interactions with these residues have been reported to be beneficial for inhibiting M pro (Rut et al., 2020; Sacco et al., 2020; Sayed et al., 2020 (Verma et al., 2020) . Furthermore, the high reactivity of Cys44 and its vicinity to the substrate-binding pocket favours it as an attractive site for covalent linkage (Verma et al., 2020) . The two compounds are clamped by several other residues from different subsites, firmly holding the compounds at the binding pocket via hydrogen bonds. These findings provide substantial evidence for the use of marine derivatives to produce the desired inhibition. Detailed MDS studies provide elegant evidence that the stability of the compounds is preserved during the simulations rendered by the RMSD and Rg profiles. The RMSF plots additionally support our findings by showing no wider variations. Additionally, the FEL projected that the protein navigated through smaller conformational spaces prior to obtaining the ensemble-equilibrated state. Our results showed that the protein was in the energy-favoured conformations (red to orange spots) (Londhe et al., 2019 ) with a few unfavourable conformations (dark blue spots), as shown in Figure 8 , (Londhe et al., 2019) . Additionally, these compounds conferred a good docking score and binding energies as compared with the reference compound, elevating their SARS-CoV-2 therapeutic ability. Furthermore, a detailed comparison was conducted to understand the structure-activity relationship (SAR) between the selected docked pose and the MDS-derived pose. Compound eri was generally static, whereas minor changes were noticed with respect to the groups from the free chain region, enabling a stable positioning at the binding pocket, as observed with the hydrogen bond residues (Fig. 11, a and b) . Furthermore, the Cys145 residue formed a π-alkyl interaction with the ligand but retained a van der Waals interaction in the MD pose. These findings shed light on the marginal movement of the ligand scaffold. Unlike eri, sob adopts a different conformation, prompting a carbon hydrogen bond interaction and producing hydrogen bond interactions with the key residue Asn142. The MD simulations also stabilised the ligand at the binding pocket firmly by adjusting the unfavourable acceptor-acceptor bond between the ligand and the residue Glu166 to van der Waals interactions. These dynamic movements have established a hydrogen bond interaction with residue Cys44. Interestingly, the residue Met165 retained its π-alkyl interaction in both the docked pose and the MD pose, indicating firm binding with the ligand (Fig. 11 , c and d). The ADMET was analysed for the selected compounds along with the reference enabling the ADMET Descriptors module available on the DS, and the results are listed in Table 3 . Furthermore, Lipinski's rule of five was calculated (Jayaram et al., 2012) (Lipinski, 2004) . Upon performing the novelty search in PubChem Compounds (Kim et al., 2016) and ChemSpider (Pence and Williams, 2010) with SMILES of the compounds as input, it was clear that these compounds have not been reported as prospective drugs against SARS-CoV-2. Taken together, our findings are evidence of the suitability of marine products for further SARS-CoV-2 clinical studies. These compounds can be adapted as starting structures for the design and synthesis of new chemical scaffolds. Diseases caused by zoonotic viruses, such as SARS-CoV-2, are a global menace (Hui et al., 2020 ) (Mackenzie and Smith, 2020) . The present study involves the use of marine drugs that are FDA approved and are currently in clinical trials. Their efficacy was computationally evaluated against SARS-CoV-2 M pro to identify potential compounds. Our detailed analysis revealed two compounds, eri and sob, as potential therapeutic compounds, and demonstrated good docking scores and displayed stable binding stabilities. The ED studies disclosed their compactness and relatively static conformation, which indicates their high potential as SARS-CoV-2 main protease inhibitors. Based on the results of our study, we propose two compounds, eri and sob, as potential leads. Further studies on these compounds, in particular experimental validation and optimisation, could be a promising strategy to fight COVID-19. Additionally, these compounds can act as chemical starting spaces for the design of new compounds. Structural insights into conformational stability of both wild-type and mutant EZH2 receptor Drug repurposing against SARS-CoV-2 using E-pharmacophore based virtual screening, molecular docking and molecular dynamics with main protease as the target Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response Proteomics of SARS-CoV-2-infected host cells reveals therapy targets Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Emerging coronaviruses: Genome structure, replication, and pathogenesis A SARS-coronovirus 3CL protease inhibitor isolated from the marine sponge Axinella cf. corrugata: Structure elucidation and synthesis Structural flexibility and protein adaptation to temperature: Molecular dynamics analysis of malate dehydrogenases of marine molluscs A review on drug repurposing applicable to COVID-19 Eribulin Mesylate: Mechanism of Action of a Unique Microtubule-Targeting Agent Putative inhibitors of SARS-COV-2 main protease from a library of marine natural products: A virtual screening and molecular modeling study Prediction of novel inhibitors of the main protease (M-pro) of SARS-CoV-2 through consensus docking and drug reposition The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 The modification of natural products for medical use LINCS: A linear constraint solver for molecular simulations The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health -The latest 2019 novel coronavirus outbreak in Wuhan VMD: Visual molecular dynamics Sanjeevini: a freely accessible web-server for target directed lead molecule discovery Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors Field-Template, QSAR, Ensemble Molecular Docking, and 3D-RISM Solvation Studies Expose Potential of FDA-Approved Marine Drugs as SARS-CoVID-2 Main Protease Inhibitors Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease Identification of potential Mpro inhibitors for the treatment of COVID-19 by using systematic virtual screening approach Genomic characterization of a novel SARS-CoV-2 Marine natural compounds as potents inhibitors against the main protease of SARS-CoV-2-a molecular dynamic study PubChem substance and compound databases Signal Transducers and Activators of Transcription (STAT) Regulatory Networks in Marine Organisms: From Physiological Observations towards Marine Drug Discovery Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs Lead-and drug-like compounds: The rule-of-five revolution Radius of gyration as an indicator of protein structure compactness Investigation of molecular details of Keap1-Nrf2 inhibitors using molecular dynamics and umbrella sampling techniques COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don't Exploring the ocean for new drug developments: Marine pharmacology The odyssey of marine pharmaceuticals: a current pipeline perspective Identifying the natural polyphenol catechin as a multitargeted agent against SARS-CoV-2 for the plausible therapy of COVID-19: an integrated computational approach Repurposing Therapeutics for COVID-19: Rapid Prediction of Commercially available drugs through Machine Learning and Docking Screening marine algae metabolites as high-affinity inhibitors of SARS-CoV-2 main protease (3CLpro): an in silico analysis to identify novel drug candidates to combat COVID-19 pandemic Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update Dieckol, a SARS-CoV 3CLpro inhibitor, isolated from the edible brown algae Ecklonia cava Polymorphic transitions in single crystals: A new molecular dynamics method Chemspider: An online chemical information resource 3-D structural interactions and quantitative structural toxicity studies of tyrosine derivatives intended for safe potent inflammation treatment Discovery of Lonafarnib-Like Compounds: Pharmacophore Modeling and Molecular Dynamics Studies A computational approach with biological evaluation: Combinatorial treatment of curcumin and exemestane synergistically regulates ddx3 expression in cancer cell lines Computational Approaches to Discover Novel Natural Compounds for SARS Old Drugs for New Purpose-Fast Pace Therapeutic Identification for SARS-CoV-2 Infections by Pharmacophore Guided Drug Repositioning Approach Old Drugs for New Purpose-Fast Pace Therapeutic Identification for SARS-CoV -2 Infections by Pharmacophore Guided Drug Repositioning Approach Pharmacophore Modelling-Based Drug Repurposing Approaches for SARS-CoV-2 Therapeutics Old Drugs for New Purpose-Fast Pace Therapeutic Identification for SARS-CoV-2 Infections by Pharmacophore Guided Drug Repositioning Approach Exploring the Therapeutic Ability of Fenugreek against Type 2 Diabetes and Breast Cancer Employing Molecular Docking and Molecular Dynamics Simulations. Evidence-based Complement SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L. Sci Microbial natural products as potential inhibitors of SARS-CoV-2 main protease (Mpro) Drug repurposing approach to fight COVID-19 Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage Challenges for Drug Repurposing in the COVID-19 Pandemic Era Revealing the molecular mechanisms of proteolysis of SARS-CoV-2 Mproby QM/MM computational methods A review of sars-cov-2 and the ongoing clinical trials GROMACS: Fast, flexible, and free Proton-Coupled Conformational Activation of SARS Coronavirus Main Proteases and Opportunity for Designing Small-Molecule Broad-Spectrum Targeted Covalent Inhibitors Bioactive compounds from marine resources against novel corona virus (2019-nCoV): in silico study for corona viral drug Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence Detailed analysis of grid-based molecular docking: A case study of CDOCKER -A CHARMm-based MD docking algorithm Molecular Dynamics Simulation of the Implantation of b-Oriented ZSM-5 Film Modified α-Quartz Substrate Surface With Different Modifiers Marine compounds and their antiviral activities The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19 Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors SARS-coV-2: An emerging coronavirus that causes a global threat SwissParam: A fast force field generation tool for small organic molecules Marine compounds as putative SARS-CoV-2 inhibitors Molecular docking and molecular dynamics simulation studies have discovered two compounds as potential SARS-CoV-2 inhibitors Eribulin mesylate (eri) and Soblidotin (sob) have demonstrated good binding affinity towards SARS-CoV-2 The authors report no conflicts of interest in this work. J o u r n a l P r e -p r o o f ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.